TD Cowen analyst Marc Frahm has maintained their bullish stance on INZY stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Frahm has given his Buy rating due to a combination of factors surrounding Inozyme Pharma’s recent developments and future prospects. The company has reported promising early data from its ENERGY-3 trial, which suggests that the treatment is providing meaningful benefits, particularly in terms of serum Pi levels. This trial, which is now fully enrolled, is pivotal for the company’s focus on ENPP1 Deficiency, and the results expected in early 2026 are anticipated to support regulatory filings in both the U.S. and EU.
Additionally, the management’s decision to concentrate resources on the development of INZ-701 for ENPP1 Deficiency, while postponing other trials, indicates a strategic focus that could enhance the company’s chances of success. The data from earlier trials, such as ENERGY-1, have shown benefits in various clinical endpoints, despite some challenges with ADA titers in younger patients. Overall, the absence of significant safety concerns and the potential for regulatory approval contribute to the positive outlook reflected in the Buy rating.
In another report released today, Needham also maintained a Buy rating on the stock with a $12.00 price target.